首页> 外文期刊>Onkologie >Borderline tumors of the ovary: Clinical course and prognostic factors
【24h】

Borderline tumors of the ovary: Clinical course and prognostic factors

机译:卵巢交界性肿瘤:临床病程和预后因素

获取原文
获取原文并翻译 | 示例
           

摘要

Background: The prognosis in borderline tumors of the ovary (BOT) is generally favorable. However, some patients experience recurrence, and mortalities occur. There is a need to better characterize prognostic factors to be considered for individualized treatment planning. Patients and Methods: The data of 158 consecutive patients who underwent surgery for BOT at a tertiary referral center for gynecologic oncology between 1997 and 2008 were retrospectively analyzed. Results: Most patients had early stage disease, and advanced stages FIGO II/III only occurred in 23.4%. Serous histology was most frequent (68%), followed by mucinous histology (22%). All patients received surgery as initial treatment with no adjuvant systemic therapy. 37 patients (40.7% of the patients under the age of 50) had fertility-sparing surgery (FSS). Recurrent disease occurred in 18 (11.4%) patients, and 4 (2.5%) patients died. Independent risk factors for recurrence were FIGO stages > I (hazard ratio (HR) 37.1; 95% confidence interval (CI) 4.5-155.5), tumor rupture (HR 12.4; 95% CI 1.5-61.5), incomplete staging (HR 5.9; 95% CI 1.6-21.3), and FSS in patients < 50 years (HR 8.0; 95% CI 2.0-31.6). Conclusion: Intraoperative tumor rupture, incomplete staging, and FSS - all influenced by the surgeon - may impose a substantial recurrence risk. Therefore, careful counseling and balancing of risk and benefit are mandatory before therapy is applied, especially if FSS is planned.
机译:背景:卵巢交界性肿瘤(BOT)的预后总体良好。但是,有些患者会复发,并会导致死亡。需要更好地表征个体化治疗计划要考虑的预后因素。患者与方法:回顾性分析了1997年至2008年间在三级妇产科肿瘤转诊中心接受BOT手术的158例患者的数据。结果:大多数患者患有早期疾病,晚期FIGO II / III仅发生在23.4%。浆液性组织学最常见(68%),其次是粘液性组织学(22%)。所有患者均接受手术作为初始治疗,无辅助全身治疗。 37例患者(50岁以下患者中占40.7%)接受了保留生育能力的手术(FSS)。复发疾病发生在18名(11.4%)患者中,而4名(2.5%)患者死亡。复发的独立危险因素为FIGO分期> I(危险比(HR)37.1; 95%置信区间(CI)4.5-155.5),肿瘤破裂(HR 12.4; 95%CI 1.5-61.5),分期不完全(HR 5.9;年龄小于50岁的患者的FSS为95%CI 1.6-21.3)和FSS(HR 8.0; 95%CI 2.0-31.6)。结论:术中肿瘤破裂,分期不完全和FSS(均受外科医生影响)可能会带来较大的复发风险。因此,在应用治疗之前,特别是如果计划进行FSS时,必须进行仔细的咨询并平衡风险和收益。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号